According to a new report published by MarkWide Research, titled, “Mycoplasma Testing Market,” the global market for mycoplasma testing is expected to exceed $1.2 billion by 2030, displaying a robust CAGR of 7.1% during the forecast period from 2023 to 2030.
Mycoplasma testing plays a critical role in ensuring the safety of biopharmaceutical and cell therapy products by detecting and preventing mycoplasma contamination. The market’s growth is driven by the expansion of biopharmaceutical manufacturing, stringent regulatory requirements, and the importance of product quality and safety.
Key findings from the report:
- Biopharmaceutical Production: Mycoplasma testing is integral to the quality control process in biopharmaceutical manufacturing.
- Regulatory Compliance: Regulatory agencies mandate mycoplasma testing to ensure the safety of biopharmaceutical products.
- Cell and Gene Therapies: The growth of cell and gene therapy development increases the demand for mycoplasma testing.
- Market Competitors: Leading players in the mycoplasma testing market include Thermo Fisher Scientific Inc., Lonza Group AG, and Charles River Laboratories International, Inc., who continually innovate to meet evolving industry demands.
The report predicts substantial growth in the global mycoplasma testing market as the biopharmaceutical industry continues to expand, and regulatory scrutiny remains high. MarkWide Research’s comprehensive analysis provides insights into the market’s current landscape and future trends, empowering industry stakeholders to make informed decisions and capitalize on opportunities in the mycoplasma testing market.
MarkWide Research is a leading market research and consulting firm, providing in-depth analysis and strategic insights across various industries. With a team of experienced analysts, MarkWide Research is committed to delivering actionable intelligence, assisting clients in making informed business decisions and achieving sustainable growth.